JPRN-jRCT2080222925未知2 期
MJR-35 phase 2 study to investigate the efficacy and safety in patients with functional dysmenorrhea
适应症
试验速览
- 阶段
- 2 期
- 入组人数
- 225
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •(1) Patients who have a painful symptom (lower abdominal pain or lumber pain) that were considered to be originated in functional dysmenorrhea in a degree of 3 points or more of dysmenorrhea score
- •(2) Patients diagnosed with functional dysmenorrhea by means of transvaginal sonography and pelvic examination
- •(3) Regular menstrual cycle length within 38 days
排除标准
- •(1) Patients with a history of either endometriosis, uterine leiomyoma, adenomyosis or secondary dysmenorrhea
- •(2) Patients with a complication of nonmenstrual painful syndrome (lower abdominal pain or lumber pain)
- •(3) Patients with severe or moderate anemia (hemoglobin less than 10.0 g/dL)
- •(4) Patient with undiagnosed abnormal genital bleeding, endometrial polyp, or endometrial hyperplasia
- •(5) Patients with a complication or history of thrombosis, embolism, cerebrovascular disorder or coronary artery disease. Patients with a predisposing factor of thrombosis.
研究者
相似试验
已完成
2 期
Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge TrialColorectal cancerJPRN-UMIN000016439Public Health Research Foundation50
进行中（未招募）
1 期
Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factorsmetastatic pancreatic carcinomaMedDRA version: 18.1Level: LLTClassification code 10033576Term: Pancreas carcinomaSystem Organ Class: 100000004864EUCTR2011-005471-17-DEKlinikum der Universität München-Großhadern150
进行中（未招募）
不适用
PGL5001 Proof of Concept study in inflammatory endometriosisEUCTR2012-001219-22-PLPregLem S.A.
已完成
2 期
Phase II study to examine efficacy prediction of Regorafenib with FDG-PET/CT in patients with treatment-refractory metastatic colorectal cancerColorectal CancerJPRN-UMIN000015563onprofit Organization Japan Clinical Cancer Research Organization20
进行中（未招募）
1 期
A study assessing the combination of TG4010 and nivolumab with standard treatment in patients with advanced non small cell lung cancer.Stage IIIB-IV non small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000015841EUCTR2016-005115-41-HUTransgene S.A.39